Languages
Pages
Legal
Explore all categories to find your favorite topic
Antibody Conjugate Therapeutics: Challenges and Potential Beverly A Teicher1 and Ravi VJ Chari2 Abstract Antibody conjugates are a diverse class of therapeutics consisting…
Large Molecule Therapeutics Development of ASG-15ME, a Novel Antibody– Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker Kendall Morrison, Pia M. Challita-Eid,…
Large Molecule Therapeutics MORAb-202 an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRa Farletuzumab and the Microtubule-targeting Agent Eribulin has Potent…
Large Molecule Therapeutics AMG 595 an Anti-EGFRvIII Antibody–Drug Conjugate Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma Kevin J Hamblett1…
Introduction ...................................................................................2 Target Validation ..........................................................................…
1. Monoclonal antibody therapeutics SLA Pharmaceutical & Health Tech. Division April 2008 Janice Reichert, Ph.D. Senior Research Fellow Tufts CSDD, Tufts University 2.…
Large Molecule Therapeutics AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for BT-Cell Malignancies and AML: A New Role…
Clin Exp Immunol 1994; 98:434-441 Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate M. BLANK, J. MANOSROIt,…
As innovative next-generation immunotherapeutic agents, antibody-drug conjugates (ADCs) are being developed worldwide as a major strategy to combat cancer and other immunological
CytomX Template 16x9_ExternalNASDAQ: CTMX platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory objectives, expected
CytomX Template 16x9_External1 Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements
Large Molecule Therapeutics An Anti-GDNF Family Receptor Alpha 1 GFRA1 Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer Sunil Bhakta…
PowerPoint Presentation© Cidara Therapeutics 2020 Forward-looking statements These slides contain forward-looking statements within the meaning of the Private Securities
Large Molecule Therapeutics Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander…
1. Developing a Bispecific Antibody as a Novel Drug Delivery System to Target Glioblastoma Stem Cells Asad Akhund, Karenna Bol, Ryan Jefferis, Kevia Qu, Jean Ye 2. SPECIFIC…
OWS Therapeutics: Monoclonal Antibody Playbook - Outpatient administration playbook (10 Nov 2020)Outpatient administration playbook 10 NOV 2020 Table of contents Activity
PowerPoint Presentationargenx Forward-Looking Statements THIS PRESENTATION HAS BEEN PREPARED BY ARGENX SE (“ARGENX” OR THE “COMPANY”) FOR INFORMATIONAL
Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis – Tandem
Abstract: Antibody-drug conjugates (ADCs) combine cytotoxic chemotherapy and antibody specificity. There are 4 components of ADC technology: the cancer, or target, antigen;
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cellsDigital Commons@Becker Digital Commons@Becker myeloma cells myeloma cells Yang Su University of California,